You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Ariad leukemia drug approved 3 months early

Federal regulators on Friday approved an Ariad Pharmaceuticals Inc. drug to treat two types of leukemia, giving the Cambridge company the green light more than three months ahead of schedule to sell the medicine in the United States.

The once-daily pill, known by its chemical name of ponatinib during years of research and clinical trials, will be marketed under the brand name Iclusig, the biotechnology company said. It was approved to treat chronic myeloid leukemia, as well as Philadelphia chromosome positive acute lymphoblastic leukemia, for patients who can’t tolerate or have developed a resistance to existing therapies.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week